BMO Capital downgraded Sabra Health Care to Market Perform from Outperform with an unchanged price target of $16. The analyst recommends taking profits with the shares up 15% over the past three months. At current levels, Sabra’s risk/reward appears more balanced, the analyst tells investors in a research note. The firm says the company’s historical multiple discount has halved versus its healthcare peers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SBRA:
- Sabra Health Care upgraded to Equal Weight from Underweight at Wells Fargo
- 2 Big Dividend Stocks Offering up to 8% Yield; Bank of America Says ‘Buy’
- BofA upgrades two skilled nursing REITs, downgrades three net lease REITs
- Sabra Health Care upgraded to Buy from Neutral at BofA
- Sabra Health Care initiated with an Outperform at Wedbush
